Eisana — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Eisana Health is a private, pre-revenue biotech startup founded in 2020, targeting a critical unmet need in oncology supportive care. The company is developing a novel, patient-centric cooling device aimed at preventing nerve damage caused by common chemotherapy agents, a condition known as CIPN which currently lacks a cure. By focusing on a home-use device, Eisana aims to improve accessibility and adherence to preventive measures. Its success hinges on clinical validation, market adoption, and navigating a competitive landscape of both established and emerging cooling technologies.

Oncology Supportive Care

Technology Platform

A patient-administered wearable cooling device system for hands and feet designed to prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN) by reducing drug exposure to peripheral nerves. Key features include usability for independent patient use from clinic to home while maintaining hand and foot function.

Opportunities

The large and growing population of cancer patients receiving neurotoxic chemotherapy creates a significant addressable market for a preventive device.

Success could establish a new standard of care in oncology supportive care, improving patient quality of life and enabling more effective chemotherapy treatment.

The 'clinic-to-home' model offers a key differentiation for patient adherence and market penetration.

Risk Factors

The primary risk is clinical, as the device may fail to demonstrate sufficient efficacy in preventing CIPN in controlled trials.

The company faces regulatory hurdles for medical device clearance and significant commercialization challenges, including establishing reimbursement and competing with existing cooling solutions.

As a pre-revenue startup, it is highly dependent on securing additional funding to reach key milestones.

Competitive Landscape

Eisana competes with existing cooling solutions like frozen gloves/socks and stationary compression cooling systems (e.g., Paxman Scalp Cooling system adapted for extremities), which are often clinic-bound and restrictive. It also faces potential competition from pharmaceutical approaches seeking to prevent or treat CIPN. Eisana's key differentiator is its focus on patient-administered, functional wearables for extended use.

More companies in Drug Delivery & Formulation →More companies in United States →